DK2440242T3 - Adjuvanssammensætning omfattende et ikke-ionisk isotonisk middel - Google Patents

Adjuvanssammensætning omfattende et ikke-ionisk isotonisk middel

Info

Publication number: DK2440242T3
Authority: DK; Denmark
Prior art keywords: isotonic agent; adjuvant composition; nonionic isotonic; nonionic; adjuvant
Prior art date: 2009-06-10

Application number

DK10721036.1T

Other languages

English (en)

Inventor

Veronique Henderickx

Dominique Ingrid Lemoine

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-10

Filing date

2010-06-08

Publication date

2014-09-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40937237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2440242(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-06-08 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2014-09-01 Application granted granted Critical

2014-09-01 Publication of DK2440242T3 publication Critical patent/DK2440242T3/da

Links

239000002671 adjuvant Substances 0.000 title 1
239000007951 isotonicity adjuster Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Dispersion Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK10721036.1T 2009-06-10 2010-06-08 Adjuvanssammensætning omfattende et ikke-ionisk isotonisk middel DK2440242T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0910046.2A GB0910046D0 (en)	2009-06-10	2009-06-10	Novel compositions
PCT/EP2010/058017 WO2010142685A1 (en)	2009-06-10	2010-06-08	Adjuvant compositions comprising a non-ionic isotonicity agent

Publications (1)

Publication Number	Publication Date
DK2440242T3 true DK2440242T3 (da)	2014-09-01

Family

ID=40937237

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK10721036.1T DK2440242T3 (da)	2009-06-10	2010-06-08	Adjuvanssammensætning omfattende et ikke-ionisk isotonisk middel

Country Status (31)

Country	Link
US (2)	US20120087976A1 (da)
EP (1)	EP2440242B1 (da)
JP (3)	JP5647677B2 (da)
KR (1)	KR101473686B1 (da)
CN (2)	CN104367997B (da)
AU (1)	AU2010257538B2 (da)
BR (1)	BRPI1012890B1 (da)
CA (1)	CA2764421C (da)
CL (1)	CL2011003113A1 (da)
CO (1)	CO6440528A2 (da)
CY (1)	CY1115522T1 (da)
DK (1)	DK2440242T3 (da)
DO (1)	DOP2011000346A (da)
EA (1)	EA024074B1 (da)
ES (1)	ES2494442T3 (da)
GB (1)	GB0910046D0 (da)
HR (1)	HRP20140792T1 (da)
IL (1)	IL216231A0 (da)
MA (1)	MA33412B1 (da)
MX (1)	MX2011013162A (da)
MY (1)	MY159819A (da)
NZ (1)	NZ596503A (da)
PE (1)	PE20120319A1 (da)
PL (1)	PL2440242T3 (da)
PT (1)	PT2440242E (da)
RS (1)	RS53550B1 (da)
SG (1)	SG176638A1 (da)
SI (1)	SI2440242T1 (da)
SM (1)	SMT201400134B (da)
UA (1)	UA104888C2 (da)
WO (1)	WO2010142685A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2668775T3 (es)	2009-06-10	2018-05-22	Chugai Seiyaku Kabushiki Kaisha	Compuestos tetracíclicos
MX355836B (es)	2010-08-20	2018-05-02	Chugai Pharmaceutical Co Ltd	Composicion que comprende compuestos tetraciclicos.
DK2651436T3 (da) *	2010-12-14	2016-06-20	Glaxosmithkline Biologicals Sa	Mycobakterie antigen sammensætning.
US10668075B2 (en)	2012-09-25	2020-06-02	Chugai Seiyaku Kabushiki Kaisha	RET inhibitor
CA2943190A1 (en) *	2014-03-25	2015-10-01	The Government Of The United States Of America As Represented By The Secretary Of The Army	Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
EP3135671B1 (en)	2014-04-25	2019-09-18	Chugai Seiyaku Kabushiki Kaisha	Novel crystal of tetracyclic compound
WO2015163448A1 (ja)	2014-04-25	2015-10-29	中外製薬株式会社	４環性化合物を高用量含有する製剤
TWI831347B (zh)	2014-08-08	2024-02-01	日商中外製藥股份有限公司	包含４環性化合物的非晶質體之固體分散體及製劑
JP6741596B2 (ja)	2015-01-16	2020-08-19	中外製薬株式会社	併用医薬
IL286493B (en)	2015-11-06	2022-07-01	Memorial Sloan Kettering Cancer Center	Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
EP3551222B1 (en) *	2016-12-07	2024-08-07	GlaxoSmithKline Biologicals SA	Process for making a liposome composition comprising a saponin
AU2018258070A1 (en)	2017-04-25	2019-10-24	Adjuvance Technologies, Inc.	Triterpene saponin analogues
WO2018220553A1 (en)	2017-05-30	2018-12-06	Glaxosmithkline Biologicals Sa	Methods for manufacturing a liposome encapsulated rna
WO2019079160A1 (en)	2017-10-16	2019-04-25	Adjuvance Technologies, Inc.	TRITERPENIC SAPONIN ANALOGS
WO2019106192A1 (en) *	2017-12-01	2019-06-06	Glaxosmithkline Biologicals Sa	Saponin purification
BR112020010635A2 (pt)	2017-12-01	2020-11-10	Glaxosmithkline Biologicals S.A.	extração de saponina
CN112384223B (zh)	2018-06-29	2024-08-27	中外制药株式会社	含有难溶性碱性药剂的药物组合物
WO2020050241A1 (ja)	2018-09-04	2020-03-12	中外製薬株式会社	４環性化合物の製造方法
WO2020109365A1 (en)	2018-11-29	2020-06-04	Glaxosmithkline Biologicals Sa	Methods for manufacturing an adjuvant
JP7640473B2 (ja) *	2019-06-05	2025-03-05	グラクソスミスクラインバイオロジカルズソシエテアノニム	サポニン精製
CA3148928A1 (en) *	2019-08-05	2021-02-11	Glaxosmithkline Biologicals Sa	Process for preparing a composition comprising a protein d polypeptide
EP4021407A1 (en)	2019-08-30	2022-07-06	GlaxoSmithKline Biologicals S.A.	Jet mixing lipid nanoparticle manufacturing process
AU2024237452A1 (en) *	2023-03-15	2025-10-23	United Immunity, Co., Ltd.	Lipid particle
WO2025180443A1 (en) *	2024-02-29	2025-09-04	Immunadd Inc.	Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5804381A (en)	1996-10-03	1998-09-08	Cornell Research Foundation	Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
SG48309A1 (en) *	1993-03-23	1998-04-17	Smithkline Beecham Biolog	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
UA56132C2 (uk) *	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19803453A1 (de) *	1998-01-30	1999-08-12	Boehringer Ingelheim Int	Vakzine
ATE513042T1 (de)	1998-02-05	2011-07-15	Glaxosmithkline Biolog Sa	Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
HK1039072A1 (zh) *	1998-05-07	2002-04-12	科里克萨有限公司	佐剂组合物及其使用方法
JP3765232B2 (ja)	2000-11-16	2006-04-12	株式会社ジェイテクト	電動式パワーステアリング装置及びこれに用いる歯車の製造方法
GB0409940D0 (en)	2004-05-04	2004-06-09	Glaxosmithkline Biolog Sa	Vaccine
GB0411411D0 (en) *	2004-05-21	2004-06-23	Glaxosmithkline Biolog Sa	Vaccines
EP1829887B1 (en) *	2004-11-29	2011-08-24	Changchun Huapu Biotechnology Co., Ltd.	Cpg single-strand deoxynucleotides for use as adjuvant
LT2351578T (lt) *	2005-06-27	2017-04-10	Glaxosmithkline Biologicals S.A.	Vakcinų gavimo būdas
TWI457133B (zh) *	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
KR20090101313A (ko)	2007-01-15	2009-09-24	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신
MX2009007572A (es)	2007-01-15	2009-10-13	Glaxosmithkline Biolog Sa	Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
KR101238795B1 (ko) *	2007-05-24	2013-03-07	글락소스미스클라인 바이오로지칼즈 에스.에이.	동결건조 항원 조성물
GB0910045D0 (en) *	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions

2009
- 2009-06-10 GB GBGB0910046.2A patent/GB0910046D0/en not_active Ceased
2010
- 2010-06-08 MA MA34506A patent/MA33412B1/fr unknown
- 2010-06-08 MX MX2011013162A patent/MX2011013162A/es active IP Right Grant
- 2010-06-08 CN CN201410497386.1A patent/CN104367997B/zh active Active
- 2010-06-08 SI SI201030689T patent/SI2440242T1/sl unknown
- 2010-06-08 CA CA2764421A patent/CA2764421C/en active Active
- 2010-06-08 SG SG2011089315A patent/SG176638A1/en unknown
- 2010-06-08 HR HRP20140792AT patent/HRP20140792T1/hr unknown
- 2010-06-08 KR KR1020127000650A patent/KR101473686B1/ko not_active Expired - Fee Related
- 2010-06-08 EA EA201190286A patent/EA024074B1/ru not_active IP Right Cessation
- 2010-06-08 UA UAA201113798A patent/UA104888C2/uk unknown
- 2010-06-08 DK DK10721036.1T patent/DK2440242T3/da active
- 2010-06-08 PT PT107210361T patent/PT2440242E/pt unknown
- 2010-06-08 PE PE2011002071A patent/PE20120319A1/es not_active Application Discontinuation
- 2010-06-08 US US13/377,425 patent/US20120087976A1/en not_active Abandoned
- 2010-06-08 CN CN201080024992.1A patent/CN102458457B/zh active Active
- 2010-06-08 AU AU2010257538A patent/AU2010257538B2/en not_active Ceased
- 2010-06-08 ES ES10721036.1T patent/ES2494442T3/es active Active
- 2010-06-08 RS RSP20140476 patent/RS53550B1/sr unknown
- 2010-06-08 NZ NZ596503A patent/NZ596503A/xx not_active IP Right Cessation
- 2010-06-08 MY MYPI2011005958A patent/MY159819A/en unknown
- 2010-06-08 EP EP10721036.1A patent/EP2440242B1/en active Active
- 2010-06-08 WO PCT/EP2010/058017 patent/WO2010142685A1/en not_active Ceased
- 2010-06-08 JP JP2012514447A patent/JP5647677B2/ja active Active
- 2010-06-08 PL PL10721036T patent/PL2440242T3/pl unknown
- 2010-06-08 BR BRPI1012890-5A patent/BRPI1012890B1/pt not_active IP Right Cessation
2011
- 2011-11-09 IL IL216231A patent/IL216231A0/en active IP Right Grant
- 2011-11-11 DO DO2011000346A patent/DOP2011000346A/es unknown
- 2011-12-07 CL CL2011003113A patent/CL2011003113A1/es unknown
- 2011-12-12 CO CO11170871A patent/CO6440528A2/es active IP Right Grant
2014
- 2014-08-29 CY CY20141100698T patent/CY1115522T1/el unknown
- 2014-09-15 SM SM201400134T patent/SMT201400134B/xx unknown
- 2014-09-26 JP JP2014196018A patent/JP5977789B2/ja not_active Expired - Fee Related
2016
- 2016-05-16 JP JP2016097525A patent/JP6261647B2/ja not_active Expired - Fee Related
2017
- 2017-07-10 US US15/645,473 patent/US20180021417A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2494442T3 (es)	2014-09-15
AU2010257538A1 (en)	2011-12-08
CN104367997A (zh)	2015-02-25
MY159819A (en)	2017-02-15
MX2011013162A (es)	2012-01-30
GB0910046D0 (en)	2009-07-22
NZ596503A (en)	2013-08-30
CL2011003113A1 (es)	2012-08-31
CY1115522T1 (el)	2017-01-04
JP2016193912A (ja)	2016-11-17
AU2010257538B2 (en)	2016-10-20
RS53550B1 (sr)	2015-02-27
CA2764421A1 (en)	2010-12-16
DOP2011000346A (es)	2012-01-15
JP2012529464A (ja)	2012-11-22
CN102458457B (zh)	2015-05-20
PL2440242T3 (pl)	2014-11-28
KR101473686B1 (ko)	2014-12-18
US20120087976A1 (en)	2012-04-12
EA024074B1 (ru)	2016-08-31
IL216231A0 (en)	2012-01-31
SMT201400134B (it)	2014-11-10
WO2010142685A1 (en)	2010-12-16
US20180021417A1 (en)	2018-01-25
JP5977789B2 (ja)	2016-08-24
KR20120031497A (ko)	2012-04-03
EP2440242A1 (en)	2012-04-18
PT2440242E (pt)	2014-08-29
SG176638A1 (en)	2012-01-30
JP6261647B2 (ja)	2018-01-17
MA33412B1 (fr)	2012-07-03
UA104888C2 (uk)	2014-03-25
EP2440242B1 (en)	2014-06-25
JP5647677B2 (ja)	2015-01-07
CN102458457A (zh)	2012-05-16
CO6440528A2 (es)	2012-05-15
CN104367997B (zh)	2019-01-22
SI2440242T1 (sl)	2014-09-30
HRP20140792T1 (hr)	2014-10-10
PE20120319A1 (es)	2012-04-16
BRPI1012890B1 (pt)	2022-03-22
BRPI1012890A2 (en)	2018-02-27
CA2764421C (en)	2016-12-06
EA201190286A1 (ru)	2012-06-29
JP2015042646A (ja)	2015-03-05

Publication	Publication Date	Title
NO2020046I1 (no)	2020-12-18	Ledipasvir - forlenget SPC
EP2518066A4 (en)	2013-07-03	NOVEL THROMBOCYTE AGGREGATION INHIBITOR
CY2017026I2 (el)	2017-11-14	Τετρακυκλικη ενωση
PL3255132T3 (pl)	2020-10-19	Kompozycja detergentu
SMT201500053B (it)	2015-05-05	2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori
SMT201600008B (it)	2016-02-25	Composti di piridazinone
SMT201600307B (it)	2016-11-10	Composizione liposomiale
EP2455446A4 (en)	2015-12-30	CLEANING AGENT COMPOSITION
PT2506716T (pt)	2017-08-24	Novos compostos tricíclicos
BRPI1016172A2 (pt)	2016-04-19	éteres diarílicos
BR112012005039A2 (pt)	2015-09-01	Composição detergente
BRPI1013588A2 (pt)	2016-04-19	composição
DOP2011000396A (es)	2012-02-15	Composiciones novedosas
DK2382009T3 (da)	2013-01-28	Bestrålingsindretning
BRPI1015474A2 (pt)	2016-04-26	composição
BRPI1013868A2 (pt)	2016-04-05	composto diaciletilenodiamina
BR112012000657A2 (pt)	2016-11-16	novos azabicilohexanos
EP2478768A4 (en)	2014-05-07	AGGREGATE AGAINST PLANT VIRUSES
UY33156A (es)	2011-07-29	Nuevos compuestos tienopirrol
EP2453284A4 (en)	2015-03-18	MICROSCOPE
DE112009005462T8 (de)	2013-03-28	Lenkungsssteuervorrichtung
EP2452679A4 (en)	2013-01-23	CELL PROTECTION PRODUCTS
BR112012005611A2 (pt)	2019-09-24	composições detergente
FR2952847B3 (fr)	2011-12-09	>
DK2516406T3 (da)	2013-10-14	Mglu2-agonister